2026-05-20T03:33:33Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/226152025-05-08T12:51:12Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16939col_20.500.12105_16962col_20.500.12105_16967col_20.500.12105_16982
Repisalud
author
Gallardo, E
author
Mendez-Vidal, MJ
author
Perez-Gracia, JL
author
Sepúlveda-Sánchez, Juan Manuel
author
Campayo, M
author
Chirivella-Gonzalez, I
author
Garcia-del-Muro, X
author
Gonzalez-del-Alba, A
author
Grande, E
author
Suarez, C
2024-09-06T09:56:41Z
2024-09-06T09:56:41Z
2018-01
Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):47-56. Epub 2017 Nov 13.
10.1007/s12094-017-1765-4
1699-3055
1699-048X
Clinical & Translational Oncology
http://hdl.handle.net/20.500.13003/9457
29134564
L619234845
2-s2.0-85033583625
https://hdl.handle.net/20.500.12105/22615
423375400007
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
eng
Kidney cancer
Systemic therapy
Molecular pathology
SEOM clinical guideline for treatment of kidney cancer (2017)
research article